1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      A β1-tubulin–based megakaryocyte maturation reporter system identifies novel drugs that promote platelet production

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p id="d8531319e277"> <div class="list"> <a class="named-anchor" id="d8531319e279"> <!-- named anchor --> </a> <ul class="so-custom-list"> <li id="d8531319e280"> <div class="so-custom-list-content so-ol"> <p class="first" id="d8531319e281">β1-tubulin–Venus reporter megakaryocyte cell line enabled high-throughput drug screening by monitoring megakaryocyte maturation. </p> </div> </li> <li id="d8531319e283"> <div class="so-custom-list-content so-ol"> <p class="first" id="d8531319e284">The identified compounds, Wnt-C59 and TCS 359, induced megakaryocyte maturation under feeder-free conditions through distinct mechanisms. </p> </div> </li> </ul> </div> </p><p class="first" id="d8531319e288">During maturation, megakaryocytes (MKs) express β1-tubulin (TUBB1) and rearrange their microtubule components to enlarge, form proplatelets, and eventually release platelets. The development of a platform to identify in vitro conditions that would efficiently promote MK development could potentially enable large-scale platelet production. Here, we show that an immortalized MK cell line (imMKCL) genetically modified to express the β1-tubulin–Venus reporter provides a practical system to efficiently monitor the in vitro production of platelet-like particles (PLPs). The Venus transgene was inserted downstream of the <i>TUBB1</i> locus in imMKCLs using CRISPR/Cas9, and the expression was visualized by Venus fluorescence intensity. This imMKCL reporter line was then used for high-throughput drug screening. We identified several compounds that significantly improved the efficiency of PLP production in vitro under feeder-free conditions and showed a significant tendency to recover platelets in vivo in a mouse thrombocytopenia model induced by anti-GPIbα antibody administration. Interestingly, most of these compounds, including a WNT signaling pathway inhibitor, Wnt-C59, antagonized the aryl hydrocarbon receptor (AhR) to increase PLP production, confirming the crucial role of AhR inhibition in MK maturation. Consistently, small interfering RNA treatment against AhR increased the Venus intensity and PLP production. TCS 359, an FLT3 inhibitor, significantly increased PLP production independently of FLT3 or AhR. This study highlights the usefulness of the β1-tubulin reporter MK line as a useful tool to study the mechanisms underlying thrombopoiesis and to identify novel inducers of ex vivo platelet production. </p><p id="d8531319e297"> <div class="fig panel" id="absf1"> <a class="named-anchor" id="absf1"> <!-- named anchor --> </a> <div class="figure-container so-text-align-c"> <img alt="" class="figure" src="/document_file/576ea624-0ae4-4c2f-902c-3cb6429f7364/PubMedCentral/image/advances019547absf1"/> </div> <div class="panel-content"/> </div> </p>

          Related collections

          Most cited references30

          • Record: found
          • Abstract: not found
          • Article: not found

          A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

          J-H Zhang (1999)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells.

            Although practiced clinically for more than 40 years, the use of hematopoietic stem cell (HSC) transplants remains limited by the ability to expand these cells ex vivo. An unbiased screen with primary human HSCs identified a purine derivative, StemRegenin 1 (SR1), that promotes the ex vivo expansion of CD34+ cells. Culture of HSCs with SR1 led to a 50-fold increase in cells expressing CD34 and a 17-fold increase in cells that retain the ability to engraft immunodeficient mice. Mechanistic studies show that SR1 acts by antagonizing the aryl hydrocarbon receptor (AHR). The identification of SR1 and AHR modulation as a means to induce ex vivo HSC expansion should facilitate the clinical use of HSC therapy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              The incredible journey: From megakaryocyte development to platelet formation

              Circulating blood platelets are specialized cells that prevent bleeding and minimize blood vessel injury. Large progenitor cells in the bone marrow called megakaryocytes (MKs) are the source of platelets. MKs release platelets through a series of fascinating cell biological events. During maturation, they become polyploid and accumulate massive amounts of protein and membrane. Then, in a cytoskeletal-driven process, they extend long branching processes, designated proplatelets, into sinusoidal blood vessels where they undergo fission to release platelets. Given the need for platelets in many pathological situations, understanding how this process occurs is an active area of research with important clinical applications.
                Bookmark

                Author and article information

                Journal
                Blood Advances
                Blood Adv
                American Society of Hematology
                2473-9529
                2473-9537
                September 11 2018
                September 11 2018
                September 11 2018
                September 11 2018
                : 2
                : 17
                : 2262-2272
                Article
                10.1182/bloodadvances.2018019547
                6134216
                30206099
                7537892b-e7df-4717-9add-b9ad8b52baf4
                © 2018
                History

                Comments

                Comment on this article